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of collateral artery development in patients with
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Objective: The purpose of the current study was to determine whether supervised exercise therapy (SET) leads to
measurable vascular adaptations in patients with intermittent claudication using contrast-enhanced magnetic resonance
angiography and ﬂow measurements.
Methods: Ten patients with clinical symptoms of intermittent claudication and proven obstructive arterial lesions of the
superﬁcial femoral artery were included and underwent SET for a period of 6 months. At baseline, all patients underwent
a treadmill test to assess pain free walking distance, ankle brachial index measurement, and magnetic resonance imaging to
determine the number of arteries in the upper leg using contrast-enhanced magnetic resonance angiography and arterial
peak ﬂow in the popliteal artery using cine phase contrast angiography. All examinations were repeated after 3 and 6
months of SET, respectively, to evaluate vascular responses relative to baseline.
Results: After 6 months of SET, mean pain free walking distance (395 6 46 m) was improved by 71% compared with
baseline (230 6 42 m; P < .01). No statistically signiﬁcant changes were found for mean values of ankle brachial index
(81 6 4 and 77 6 4, respectively, at baseline and after 6 months of SET), number of arteries at the level of the arterial
lesion (18 6 2 and 19 6 2, respectively) nor arterial peak ﬂow (5.3 6 0.6 and 5.3 6 0.8 mL/s, respectively).
Conclusions: SET in patients with intermittent claudication results in an increase in pain free walking distance, whereas
with magnetic resonance imaging no macrovascular adaptations in terms of additional collateral artery formation or ﬂow
increases could be observed. (J Vasc Surg 2013;58:1236-43.)Peripheral arterial disease (PAD) is a major health care
problem among the elderly in Western society,1,2 affecting
up to 7% of the general population over the age of 70
years.2 Symptoms in these patients range from intermittent
claudication (Fontaine stage II, Rutherford stage 1-33) to
critical limb ischemia.1
The primary aim of treatment, in symptomatic patients
with PAD without signs of critical ischemia, is relief of
symptoms by improving exercise performance. Structured
or supervised exercise therapy (SET) has been shown to
be an effective conservative therapeutic approach to achieve
this aim.2,4-7 Improvement in exercise performance with
SET is well established,5-8 but the magnitude of the
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6Although SET is the primary choice of treatment in
intermittent claudication, the exact physiological mecha-
nisms by which clinical improvement is accomplished are
still subject to debate.6 Stimulating collateral artery forma-
tion to increase muscle perfusion is thought to be a poten-
tially contributing biological mechanism,2,6,7,9-12 which is
generally thought to be a response to exercise induced
elevated vessel wall shear stress.13,14 Collateral artery
formation is a complicated process and is thought to
involve both adaptation of existing arteries and the forma-
tion of novel collateral arteries over time.15 To date, the
exact conditions under which collateral formation take
place in patients with PAD, as well as determinants of vari-
ations in extent of collateral formation among patients, are
still poorly understood.
Magnetic resonance imaging (MRI) is an ideal modality
to study the process of vascular adaptations in the context
of SET because it is highly reliable for depiction of the
peripheral vascular tree 16-18 and has the ability to quantita-
tively study physiological phenomena such as vascular ﬂow.
The purpose of this study was to assess the morpho-
logic and functional macrovascular adaptations in response
to SET in patients with intermittent claudication. Morpho-
logic effects were evaluated with contrast-enhanced
magnetic resonance angiography (CE-MRA), whereas
functional effects were assessed using quantitative ﬂow
measurements.
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Study population. Patients with newly diagnosed
symptoms of PAD (Fontaine stage II; intermittent claudi-
cation with no signs of critical ischemia3) were eligible
for participation in this study if obstructive arterial lesions
(ie, signiﬁcant stenosis [>50%] and/or occlusion) of the
superﬁcial femoral artery (SFA) were detected by duplex
ultrasonography (peak systolic velocity ratio > 2.019).
Focus in this study was on patients with SFA disease as
these patients are known to respond best to SET, whereas
patients with obstructive lesions within the iliac arteries are
more often referred for invasive therapy and more likely to
drop out of SET. Patients with lower leg stenosis are more
prone to have diabetes, in which collateral artery formation
might be impaired.20-22 Therefore, diabetic patients and
patients with signiﬁcant arterial lesions in the aorta, iliac
arteries, or arteries below the knee were excluded. If
signiﬁcant arterial lesions were detected in either the
infrarenal aorta or severe lesions were detected in the lower
leg on CE-MRA after initial inclusion of a patient, they
were excluded from further participation from this study;
however, this scenario did not occur during the entire
study. Additional exclusion criteria were prior treatment for
PAD and presence of chronic or acute critical ischemia.
Patients scheduled for vascular surgery or percutaneous
transluminal angioplasty were also excluded from partici-
pation, as well as patients with contraindications to
MRI, including claustrophobia, known gadolinium-based
contrast agent allergy, and low estimated glomerular
ﬁltration rate (<30 mL/kg/1.73 m2) or patients with
contraindications for SET. The study was approved by the
institutional medical ethics committee, and all patients gave
written informed consent before inclusion.
Study design. Upon entry in the study, all patients
underwent a treadmill test, ankle brachial index (ABI)
measurement and MRI as described below to establish
baseline values. MRI was acquired ﬁrst, followed by the
ABI measurements and the treadmill test on the same
day (Fig 1). All examinations were repeated after 3 and
6 months of SET, respectively. Patients did not receive
other (invasive) therapy than SET during this period, nor
were there any alterations in prescribed medicaments. After
6 months of SET, patients returned to their vascular
surgeon for evaluation and to discuss further treatment
options (ie, (dis)continuing SET and/or invasive therapy).
Participation in this study had no impact on the course of
treatment for the patients. MRI data were not used in the
clinical evaluation of the participants.
SET and treadmill testing. A standardized and
graded treadmill protocol was used during both the tread-
mill tests as well as the subsequent SET, as previously
described by Gardner et al.23 In this widely accepted and
validated protocol,23 a constant speed of 3.2 km/h was
applied, whereas during the exercise the slope of the
treadmill was increased by 2% every 2 minutes starting at
0% inclination, thereby gradually increasing the metabolic
demand for the patient. SET consisted of walking exerciseson a treadmill two to three times per week, supervised by a
physiotherapist. In addition, patients were given instruc-
tions for individual walking exercises.
To assess the effect of SET on pain free walking distance,
treadmill tests were performed after 3 and 6 months at the
vascular laboratory of our institution.
MRI protocol. MRI was performed to determine
morphologic and functional vascular effects during SET.
Morphologic effects were studied using CE-MRA,
whereas functional effects were studied using quantitative
two-dimensional cine magnetic resonance phase-contrast
imaging to determine the arterial peak ﬂow (APF) of the
popliteal artery both at rest and after provoking reactive
hyperemia to determine the maximum hyperemic ﬂow as
described before.24,25 Postischemic reactive hyperemia in
the lower leg was provoked using an inﬂatable cuff, en-
suring total arterial occlusion (Medrad, Indianola, Pa). The
cuff was placed at midthigh level and manually inﬂated to
suprasystolic values (>50 mm Hg above brachial systolic
blood pressure) during 6 minutes. During cuff inﬂation,
ﬂow in the popliteal artery (PA) was measured with cine
phase-contrast imaging to check that total arterial occlusion
of the upper leg was achieved. A schematic overview of the
study and MRI measurements is given in Fig 1.
All examinations were performed on a 1.5-T MRI
system (Intera; Philips Medical Systems, Best, The
Netherlands). For signal reception, we used a dedicated
12-element phased-array peripheral vascular coil with a cra-
niocaudal coverage of 128 cm (Philips Medical Systems).
Patients were imaged in supine position and were in this
position for approximately 30 minutes before the ﬂow
measurement was started to minimize any confounding
history of physical effort. During this time the CE-MRA
was acquired, using a ﬁxed dose of 10 mL gadofosveset tri-
sodium (Ablavar; Lantheus Medical Imaging, Billerica,
Mass) as contrast agent.
Survey. A nonenhanced time-of-ﬂight scan of the
pelvic, upper, and lower leg station was acquired to prescribe
the imaging volumes of interest for morphologic and func-
tional imaging. For this, a turbo ﬁeld echo pulse sequence
was used with a 180 inversion prepulse to suppress
stationary tissues. Thirty-one axial slices per station were
acquired with 3.3-mm slice thickness and 11-mm interslice
gap and an inferiorly concatenated saturation band.
The standard quadrature body coil was used for signal
transmission and reception. For positioning of the three-
dimensional CE-MRA volumes maximum intensity projec-
tions were generated in three orthogonal directions.
Angiography. A one-station three-dimensional gradient-
echo sequence was used for ﬁrst-pass CE-MRA as previously
described.16,26 Whereas clinical CE-MRA examinations are
usually limited to the visualization of a thin anteroposterior
imaging volume only including the large conduit arteries in
the upper leg (ie, SFA and PA), for this study, the entire
muscular volume of the upper leg was imaged to visualize all
the arteries including any collateral branches within the upper
leg. Acquisition parameters were as follows: repetition time
Fig 1. Overview of the study and magnetic resonance imaging (MRI) measurements. MRI was performed ﬁrst, fol-
lowed by ankle brachial index (ABI) measurements and treadmill tests during each visit of the patient. During the MRI
examination, a ﬁrst-pass contrast-enhanced magnetic resonance angiography (CE-MRA) was performed of the entire
muscular volume of the upper leg. CE-MRA was followed by quantitative cine phase-contrast imaging (PCI) to
measure the arterial peak ﬂow (APF) at rest and after provoking reactive hyperemia by a cuff paradigm.
JOURNAL OF VASCULAR SURGERY
1238 Versluis et al November 2013(TR) 4.8 ms, echo time (TE) 1.45 ms, ﬂip angle 40, ﬁeld-of-
view (FOV) 470 mm, matrix 480  480, and voxel dimen-
sions (reconstructed) 0.92  0.92  1.20 mm. Prior to
contrast medium administration, a nonenhanced “mask”
image data set was acquired with exactly the same acquisition
parameters as the CE-MRA, enabling background tissue
suppression by image subtraction.
After the ﬁrst-pass sequence, a three-station nonsub-
tracted high-resolution steady-state acquisition was applied
to visualize the entire peripheral vascular tree to exclude
iliac and lower leg arterial obstructions.
Flow MRI. For quantitative ﬂow measurements we
used a two-dimensional gradient-echo cine phase contrast
angiographic scan technique with the following acquisition
parameters: TR 9.7 ms, TE 5.8 ms, ﬂip angle 30, FOV
380 mm, matrix 384, and reconstructed voxel dimensions
of 0.99  0.99  6.00 mm. Fifteen dynamic phases were
acquired to obtain ﬂow waveforms over the cardiac cycle.
The phase encoding velocity was set to 100 cm/s in the
craniocaudal direction.17,24 Vector cardiography trigger-
ing was used for retrospective cardiac synchronization.
Parallel imaging (SENSitivity Encoding [SENSE]) was
applied to reduce scan time (SENSE acceleration factor 2
in the anterior-posterior direction).27 At a mean heart rate
of 60 beats per minute, the nominal acquisition time was
1 minute.
ABI measurements. All ABI measurements were per-
formed by well-trained operators at our vascular function
laboratory, using an automated Doppler system (Nicolet
VasoGuard; VIASYS Healthcare, Madison, Wisc). If the
ABI could not be determined because of arterial stiffness orother circumstances, this was mentioned in the report by
the operators.
Angiographic reading. All angiographic data sets
were analyzed by a well-trained radiologist with over
5 years of experience in CE-MRA of the peripheral
vasculature. First-pass CE-MRA data sets were used to
assess morphologic vascular effects following SET.
Image analysis of the ﬁrst-pass acquisition to determine
the number of arteries of the upper leg was performed on
a dedicated image postprocessing workstation (MacPro,
running OS X, v. 10.5.4; Apple Inc, Cupertino, Calif).
As contrast-enhanced source images have shown better
reproducibility compared with subtracted images, source
images were considered for analysis.17 The number of
arteries was manually quantiﬁed by counting the total
number of arteries crossing transverse planes in the upper
leg at three different levels: 5 cm above, exactly at, and at
5 cm below the location where the SFA was reconstituted
distal to the occlusion (Fig 2).17 This method ensures
complete coverage of the collateral re-entrance zone,
which represents the level at which collaterals re-enter the
large native conduit artery distal to an occluded segment
of the arterial tree (distal superﬁcial femoral or popliteal
artery in our study). Arteries were counted using the
open source DICOM viewer OsiriX (OsiriX, Geneva,
Switzerland, v. 3.5.1, http://www.osirix-viewer.com/),
using the original source images as well as coronal and
sagittal multiplanar reconstructions. Identiﬁcation of the
correct counting plane was ensured by cross-reference to
the anatomic landmarks as described above. Subsequently,
the total number of arteries intersecting the three planes
Fig 2. Example of the counting procedure of the arteries in the upper leg using ﬁrst-pass contrast-enhanced magnetic
resonance angiography (CE-MRA) data set. Arteries are marked in the right panel by the gray dots. Fifteen arteries were
counted in this axial view.
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terminal muscle branches and any visible collateral arteries
(Fig 2). Arteries were distinguished from veins by scrolling
through source images and multiplanar reconstruction
stacks to ﬁnd an upstream connection to a named artery.
Flow analysis. Modulus and phase images were recon-
structed from the cine phase contrast data. A quantitative
ﬂow analysis package included with the software release
(Qﬂow, R11.4.14; Philips Medical Systems) of the MRI
hardware was used for analysis of the ﬂow waveform data.
Using this software, a region-of-interest covering the entire
visible cross-section of the artery of interest was manually
drawn using a reconstructed modulus image during peak
systole and then automatically propagated to the remaining
cardiac phases using an active contour algorithm. Although
the peak systolic phase is sufﬁcient to calculate the APF,
regions-of-interest were propagated to all cardiac phases to
obtain ﬂow wave forms, which were visually analyzed to
reassure that the chosen cardiac phase indeed was at peak
systole and to detect possible aliasing effects directly after the
acquisition. If detected, the measurement was repeated with
sufﬁcient higher phase encoding velocity. APF was preferred
over mean ﬂow for analysis, as peak ﬂow previously proved
much more reproducible and revealed large differences
between patients and healthy controls.17,24,25 Given the
good inter-reader reproducibility of the APF analysis, all ﬂow
measurements were anonymously analyzed by a single,
experienced radiologist.17,25
Statistical analysis. For statistical analysis, only data of
the symptomatic leg was used. If both legs were equally
symptomatic, only the right leg was analyzed. Statistical
analysis was performed with commercially available statis-
tical software (SPSS 16.0; SPSS Inc, Chicago, Ill). Meanvalues derived from baseline and follow-up measurements
were compared and tested for statistical signiﬁcance using
a t test for paired samples. P value of <.05 was considered
statistically signiﬁcant.
RESULTS
Subjects. Over a period of 6 months, 10 patients
(mean age 72.8 6 8.9 years; range 60-84 years; 8 men
and 2 women) were included. SET was well tolerated by
all patients. Subjects underwent 6 months of SET and three
MRI examinations as planned without experiencing side
effects or adverse events.
Effect of SET on pain free walking distance. Mean
baseline pain free walking distance, as well as pain free
walking distances after 3 and 6 months of SET, are listed
in the Table. After 3 months of SET, the average pain
free walking distance was signiﬁcantly higher (P < .01)
compared with the baseline distance at group level. After
6 months of SET, pain free walking distance improved by
71% on average compared with baseline values (P < .01).
The increase at 6 months relative to 3 months was small
and not signiﬁcant (P ¼ .45). In two out of 10 patients,
pain free walking distance did not increase.
MRA. At baseline, a signiﬁcant arterial stenosis (n ¼ 6)
or occlusion (n ¼ 4) was present in the SFA in all patients.
Morphologically, the arterial lesions of most patients
remained unchanged (Fig 3), although in two patients
there was evident progression of the arterial lesions after
6 months (Fig 4), whereas clinical symptoms (ie, pain free
walking distance) in these patients remained unchanged.
Collateral arteries were present in six out of 10 patients at
baseline. The mean number of arteries in the upper leg at
three different levels before and after SET is listed in the
Table. Baseline and follow-up results after 3 and 6
months of SET, respectively
Baseline 3 months 6 months
SET
Pain free walking
distance (m)
230 6 42 362 6 53a 395 6 46a
Number of arteries
5 cm above lesion 23 6 3 21 6 3 20 6 3
At lesion level 18 6 2 18 6 3 19 6 2
5 cm below lesion 12 6 1 12 6 1 12 6 1
APF (mL/s)
At rest (n ¼ 10) 5.3 6 0.6 5.5 6 0.8 5.3 6 0.8
Maximum hyperemic
ﬂow (n ¼ 6)
7.1 6 3.5 7.8 6 3.3 7.5 6 2.4
Ankle-brachial index 81 6 4 80 6 4 77 6 4
APF, Arterial peak ﬂow; SET, supervised exercise therapy.
Values are mean 6 standard error.
aP < .01 compared with baseline.
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arteries after 3 and 6 months of SET, respectively, compared
with baseline values. In one of the two patients in whom the
pain free walking distance did not improve, collateral arteries
were present at baseline, whereas in the other, no collateral
arteries were present at baseline nor developed during SET.
APF. Results of APF measurements are also listed in the
Table. As was the case with the number of collateral arteries,
mean APF at rest did not change signiﬁcantly from the
baseline value after 3 and 6 months of SET. Fig 3 shows an
example of the APF at the level of the popliteal artery before
and after SET in a patient that responded well to SET.
Measurement of the maximum hyperemic ﬂow after
provoking reactive hyperemia with a cuff paradigm succeeded
in six patients, whereas in four patients the cuff paradigm
proved too painful and cuff inﬂation could not be maintained
for 6 minutes. In those six patients with successful hyperemic
measurements, the maximum hyperemic ﬂow did not change
signiﬁcantly from baseline values either (Table).
ABI measurements. ABI measures before and after 3
and 6 months of SET are listed in the Table. In two
patients, the ABI could not be determined reliably, because
of uncompressible arteries at the level of the ankle. After 3
and 6 months of SET, the mean ABI did not differ
signiﬁcantly from the baseline value.
DISCUSSION
In this study, we assessed the macrovascular effects of
6 months of SET in patients with intermittent claudication
using different MRI techniques. The main ﬁnding of this
study is that although pain free walking distance improved
substantially and signiﬁcantly, no vascular adaptations in
terms of development of newly visible collateral arteries
and/or increase in APF could be detected with MRI.
Effect of SET on walking distance. Many studies
have shown the beneﬁts of SET to increase pain free and
maximum walking distance in patients with intermittent clau-
dication.2,4-8,28-31 Our study corroborates prior work and
provides further evidence in support of this highly effectiveand low-cost intervention. The strongest improvement was
made during the ﬁrst 3 months of therapy, during which the
pain free walking distance increased signiﬁcantly compared
with baseline values. Between the third and sixth months,
there was a trend of further improvement in walking
performance, but improvements were less pronounced.
SET and collateral artery development. No new
collateral arteries were found in our study population when
comparing both maximum intensity projections as well as
artery counts using our standardized counting method at
different timepoints. On the contrary, in two patients, arte-
rial lesions increased in severity over time (Fig 4).
Maximum intensity projections of CE-MRA data
acquired at baseline revealed that most patients already
had collateral arteries before the start of SET. The aspect
of these collateral arteries did not change on MRA after
6 months of SET. Conversely, patients without collaterals
at the start of SET did not develop any new visible collat-
erals during SET. These ﬁndings are remarkable, as SET is
thought to stimulate formation of collateral arteries.6 Two
patients in whom the pain free walking distance did not
improve after SET, showed presence of collateral arteries
at the start of SET already.
APF. As with MRA, the APF measured at the level of
the popliteal artery (ie, below the level of the arterial stenosis
in the SFA and below the level of the suspected collateral
artery re-entrance zone) did not reveal any improvement
after 3 or 6 months of SET, both at rest and after provoking
reactive hyperemia (maximum hyperemic ﬂow25). Even
though there were no morphologic vascular adaptations, an
increase in APF might still have been expected because of
a possibly improved physical condition, especially where the
hyperemic ﬂow is concerned, yet APF results were in line
with MRA ﬁndings. This means that clinical improvement of
our patients cannot be explained by either morphologic or
functional vascular changes, as far as could be detected with
MRI at rest and after provoking hyperemia.
ABI. The ABI was measured to correlate possible
functional vascular improvements (ie, increased APF) with
a well-established and clinically widely applied functional
test. Results in this study show that although the pain free
walking distance of patients did increase, there was no
increase in ABI after, respectively, 3 and 6 months of SET,
respectively, which is in line with Watson et al,30 who did not
ﬁnd changes in ABI during SET either. These results are also
comparable with MRI ﬁndings, where no vascular adapta-
tions or collateral artery formation was detected either.
Considerations. Although the study population was
relatively small, we found no signs of macrovascular adapta-
tions with MRI, whereas there was a signiﬁcant improve-
ment in pain free walking distance after 6 months of SET
in a high proportion of the participants. It is unlikely
we missed signiﬁcant collateral artery formation or improve-
ments in ﬂow as CE-MRA has a high sensitivity for detecting
small arteries17 and both CE-MRA as well as phase-contrast
ﬂow imaging proved highly reproducible before.17,25 Given
the observation that collateral arteries were already present in
the majority of the included patients, it is more likely that
Fig 3. Example of a maximum intensity projection of contrast-enhanced magnetic resonance angiography (CE-MRA)
(upper panels) and the arterial ﬂow wave form (lower panels) of a responder to supervised exercise therapy (SET) (pain
free walking distance increased from 100 to 333 m after 6 months of SET). The arterial obstruction in the superﬁcial
femoral artery (SFA) is indicated by the white arrow. The three white lines demarcate the three axial planes where
arteries were counted. The white dotted lines represent the location of the arterial peak ﬂow (APF) measurement. No
vascular morphologic or APF (black arrows) changes were seen after 6 months of SET.
Fig 4. Progression of arterial lesions (left, white arrow) in the
right leg of a patient with intermittent claudication. At the level of
the popliteal artery, a new stenosis has developed (right, small
white arrows) compared with the baseline magnetic resonance
angiography (MRA) (left).
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collateral arteries had already been developed to a maximum
extend and started to fall short.Most patients in this study responded favorably to SET
and improved clinically. Nevertheless, the success of SET
does not seem to be related to a (macro) vascular substrate.
Many participating patients declared that in their opinion the
improved pain free walking distance was actually the result
of “a better handling” of pain. Although we did not investi-
gate this aspect, it could potentially explain the discrepancy
between clinical and MRI ﬁndings in this study.32
This study demonstrates that active monitoring of SET
with MRI is not helpful to unveil any contribution of mac-
rovascular adaptations, and MRI cannot help at the early
detection of possible nonresponders. From a basic research
point of view, it might be helpful to acquire MRI data of
PAD patients in earlier stages of disease, during which no
collateral arteries are present yet.
Even though MRI in this study was not able to detect
macrovascular changes, our technique might still be useful
for the monitoring and follow-up of patients with PAD
treated with other, new therapeutic options aiming to
improve vascularization, such as with stem cells and
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factor and basic ﬁbroblast growth factor), which are
currently being developed for treatment of both intermit-
tent claudication and critical ischemia.33-36
Finally, our study underscores the need for MR
methods to study adaptations at tissue level. However,
although some authors have investigated skeletal muscle
oxygenation and perfusion,37-39 questions remain about
the reproducibility of these techniques, at least at a
magnetic ﬁeld strength of 1.5 T.17
CONCLUSIONS
SET in patients with intermittent claudication results in
an increase in pain free walking distance. Nevertheless, with
the current approach MRI proved not able to detect mac-
rovascular adaptations in terms of additional collateral
artery formation or ﬂow increases both at rest and during
reactive hyperemia after 6 months of SET compared with
baseline values.
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The improvement in pain free walking distance with exercise
by patients with claudication may rival that achieved with interven-
tion.1 The mechanisms underlying this improvement are believed
to be the enlargement of existing collaterals and development of
new vessels in response to the repeated demand for additional
ﬂow. Certainly, there are impressive differences in collateral devel-
opment between patients with similar obstructions to inline arterial
ﬂow, but how much of this represents existing vessel dilation or
new vessel development and to what degree a rich collateral bed
is intrinsic to the unique anatomy and biology of the individual
affected remain important unanswered questions.
In this issue of the Journal of Vascular Surgery, Dr Versluis
and colleagues have attempted to add science to the mystery.2
They studied 10 patients using contrast-enhanced magnetic reso-
nance angiography to assess collateral number before and after
a 6-month supervised exercise program. Pain free walking distance
improved by 71%, but the number of collaterals identiﬁed, peak
arterial ﬂow, and ankle brachial index values did not.
Versluis’ study is not deﬁnitive. The number of patients is
small, ﬂow measurements were made in only six of the 10 subjects,
and collateral development could have been below the level of
detection with contrast-enhanced magnetic resonance angiog-
raphy. Nonetheless, their study adds to others suggesting that
the response to exercise may be much more complex than simplyincreasing blood ﬂow. For example, arm-ergometry is reported to
increase walking distance in claudicants.3 The response to exercise
in peripheral artery disease begs for carefully performed prospective
studies with more sensitive methods for collateral assessment,
documentation of systemic and skeletal muscle responses, and
biomarker assays. It is hoped that Versluis and colleagues will
continue to reﬁne their work and stimulate others to join in this
important effort.REFERENCES
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